Erratum: Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production (Journal of Clinical Investigation (2014) 124:2 (509-514) DOI:10.1172/JCI70704);Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 509-514

  Merovci, Aurora ^a   Solis Herrera, Carolina ^a   Daniele, Giuseppe ^a   Eldor, Roy ^a   Vanessa Fiorentino, Teresa ^a   Tripathy, Devjit ^a   Xiong, Juan ^a   Perez, Zandra ^a   Norton, Luke ^a   Abdul Ghani, Muhammad A ^a   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; GLUCOSURIA; GLUCOTOXICITY; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; MIDDLE AGED; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXICITY;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; GLUCAGON; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSIDES; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; METFORMIN; MIDDLE AGED; MUSCLES; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 84893827104     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76184     Document Type: Erratum

References (28)

1. He Z, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am. 2004; 33(1):215-238.
2. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13(6):610-630.
3. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin. J Clin Invest. 1987;79(5):1510-1515.
4. Lindmark S, Burén J, Eriksson JW. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: potential impact for glucotoxicity in vivo. Clin Endocrinol (Oxf). 2006;65(3):301-309.
5. Burén J, Lindmark S, Renström F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism. 2003; 52(2):239-245.
6. Zierath JR, Galuska D, Nolte LA, Thörne A, Kristensen JS, Wallberg-Henriksson H. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance. Diabetologia. 1994; 37(3):270-277.
7. Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab. 2012;97(12):4682-4691.
8. Vourinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes. 1992; 41(5):571-580.
9. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035.
10. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982;5(4):353-363.
11. Mayorov AY, Naumenkova IV, Antsiferov MB, Dedov II. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients. Diabetes Res Clin Pract. 2005;68(suppl 1):S54-S59.
12. Groop LC, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84(1):205-213.
13. Belfort R, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005;54(6):1640-1648.
14. Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035.
15. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515-531.
16. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981;30(12):1000-1007.
17. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387-395.
18. DeFronzo RA, Ferrannini E. Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev. 1987;3(2):415-460.
19. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48(5):1198-1214.
20. Matsuda M, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism. 2002;51(9):1111-1119.
21. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92(2):158-169.
22. Meyer C, Gerich JE. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep. 2002; 2(3):237-241.
23. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol. 1999;276(1 pt 1):E78-E84.
24. Gustavson SM, et al. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism. 2004;53(7):933-941.
25. DeFronzo RA, Andres R, Bledsoe TA, Boden G, Faloona GA, Tobin JD. A test in man of the hypothesis that the rate of fall in glucose concentration triggers counter-regulatory hormonal response. Diabetes. 1977;26(5):445-452.
26. Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci. 2009; 14:1169-1181.
27. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique. A method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214- E223.
28. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol. 1956; 187(1):15-24.